Business Context and Reporting Period
This Form 8-K Current Report is filed by Vivos Therapeutics, Inc. (NASDAQ: VVOS) on June 16, 2026, regarding an event that occurred on June 11, 2026. The filing announces the Company's intention to file a registration statement with the SEC for a proposed rights offering.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the proposed capital structure event.
Material Changes and Proposed Offering Terms
The Company intends to distribute transferable subscription rights as a dividend to shareholders. Key preliminary terms include:
- Record Date: Proposed to be the 30th day following the SEC declaration of the registration statement effective.
- Initial Exercise Price: The greater of $1.25 per share or 20% above the market price on the day before the record date.
- Exercise Period: Expected to be nine months.
- Subsequent Rights: Upon exercise, holders are expected to receive a subsequent nine-month trading right with an exercise price equal to the greater of $1.75 per share or 40% above the market price on the day before the record date.
- Trading: Rights are intended to be listed for trading on a securities exchange, subject to regulatory requirements.
Guidance, Risks, and Contingencies
The proposed rights offering is subject to numerous conditions that could delay, alter, or prevent its completion. Management commentary highlights the following risks and contingencies:
- Regulatory Approval: The offering is contingent on the SEC declaring the registration statement effective.
- Shareholder Approval: May be required if the number of authorized but unissued shares is insufficient, necessitating an amendment to the certificate of incorporation.
- Market Conditions: Prevailing market conditions and the ability to access capital on acceptable terms.
- Termination Rights: The Company reserves the right to modify, postpone, or terminate the offering at any time prior to completion.
- Tax Uncertainty: Uncertain tax treatment for shareholders regarding the receipt, ownership, sale, or exercise of the rights.
The filing includes a standard cautionary note regarding forward-looking statements, noting that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the final terms of the rights offering in the prospectus once the registration statement is declared effective by the SEC.
- Confirm whether shareholder approval is required to authorize additional shares for the offering.
- Monitor the Company's filings for updates on the record date and the final exercise price.
- Review the Company's current authorized share count to assess the likelihood of needing a charter amendment.
- Consult tax advisors regarding the potential tax implications of receiving and exercising the subscription rights.